Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases

被引：39

作者：

Ghosh, Debjani ^{[1
]}

Tsokos, George C. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02115 USA

来源：

AUTOIMMUNITY | 2010年 / 43卷 / 01期

关键词：

Inflammation; autoimmunity; kinases; T-CELL-RECEPTOR; INDUCED NEUTROPHIL ACTIVATION; SYK KINASE; SIGNAL-TRANSDUCTION; ZETA-CHAIN; LINKER REGION; ANTIGEN; ZAP-70; LUPUS; INHIBITOR;

D O I：

10.3109/08916930903374717

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Spleen tyrosine kinase (Syk) is involved in the development and function of B and T cells, the Fc receptor-mediated degranulation of basophils and mast cells. Recent work has assigned important roles for Syk in the aberrant function of T cells in patients with systemic lupus erythematosus (SLE), osteoclasts, and urate crystal-induced neutrophil stimulation. Preclinical and early clinical studies have urged Syk inhibition for the treatment of patients with rheumatoid arthritis, whereas ex vivo experiments and preclinical studies point to a therapeutic potential of Syk inhibition in patients with SLE and crystal-induced arthritides.

引用

页码：48 / 55

页数：8

共 77 条

[1] Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].

Anolik, JH ;

Barnard, J ;

Cappione, A ;

Pugh-Bernard, AE ;

Felgar, RE ;

Looney, RJ ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590

[2] DEFECTIVE T-CELL RECEPTOR SIGNALING AND CD8(+) THYMIC SELECTION IN HUMANS LACKING ZAP-70 KINASE [J].

ARPAIA, E ;

SHAHAR, M ;

DADI, H ;

COHEN, A ;

ROIFMAN, CM .

CELL, 1994, 76 (05) :947-958

[3] The structure, regulation, and function of ZAP-70 [J].

Au-Yeung, Byron B. ;

Deindl, Sebastian ;

Hsu, Lih-Yun ;

Palacios, Emil H. ;

Levin, Susan E. ;

Kuriyan, John ;

Weiss, Arthur .

IMMUNOLOGICAL REVIEWS, 2009, 228 :41-57

[4] An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus [J].

Bahjat, Frances Rena ;

Pine, Polly R. ;

Reitsma, Andrea ;

Cassafer, Gail ;

Baluom, Muhammad ;

Grillo, Sunny ;

Chang, Betty ;

Zhao, Fei Fei ;

Payan, Donald G. ;

Grossbard, Elliott B. ;

Daikh, David I. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1433-1444

[5] Crystal-induced neutrophil activation VI.: Involvement of FcγRIIIB (CD16) and CD11b in response to inflammatory microcrystals [J].

Barabé, F ;

Gilbert, C ;

Liao, N ;

Bourgoin, SG ;

Naccache, PH .

FASEB JOURNAL, 1998, 12 (02) :209-220

[6] PROTEIN-TYROSINE PHOSPHORYLATION - AN ESSENTIAL COMPONENT OF FC-EPSILON-RI SIGNALING [J].

BENHAMOU, M ;

SIRAGANIAN, RP .

IMMUNOLOGY TODAY, 1992, 13 (06) :195-197

[7] Kinase inhibitors for the treatment of inflammatory and autoimmune disorders [J].

Bhagwat, Shripad S. .

PURINERGIC SIGNALLING, 2009, 5 (01) :107-115

[8] Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets [J].

Bhavaraju, Kamala ;

Kim, Soochong ;

Daniel, James L. ;

Kunapuli, Satya P. .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 580 (03) :285-290

[9] R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation [J].

Braselmann, Sylvia ;

Taylor, Vanessa ;

Zhao, Haoran ;

Wang, Su ;

Sylvain, Catherine ;

Baluom, Muhammad ;

Qu, Kunbin ;

Herlaar, Ellen ;

Lau, Angela ;

Young, Chi ;

Wong, Brian R. ;

Lovell, Scott ;

Sun, Thomas ;

Park, Gary ;

Argade, Ankush ;

Jurcevic, Stipo ;

Pine, Polly ;

Singh, Rajinder ;

Grossbard, Elliott B. ;

Payan, Donald G. ;

Masuda, Esteban S. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :998-1008

[10]

CAMBIER JC, 1995, J IMMUNOL, V155, P3281

← 1 2 3 4 5 6 7 8 →